A renoprotective effect of enalapril in chronictransplantation nephropathy

Abstract


Aim. To study safety and efficacy of ACE inhibitor enalapril in chronic transplantation nephropathy
(CTN) as well as nephroprotective efficacy of this drug in various clinical variants of CTN.
Material and methods. A retrospective study covered 220 recipients with CRF. The patients were divided into the study group (n = 103) and the control group (n = 117). The study group was given
ACE inhibitor enalapril the efficacy of which was assessed by arterial pressure (systolic, diastolic,
mean) dynamics, 24 h proteinuria and the rate of CTN progression. This rate was suggested by probability of plasm creatinin doubling (Kaplan-Meier technique).
Results. Enalapril significantly inhibited CTN progression running with minimal or marked proteinuria, had a pronounced hypotensive effect, promoted stabilization of minimal proteinuria (in CTN with
minimal proteinuria) or reduction of protein excretion (in a proteinuric variant of CTN).
Conclusion. Use of enalapril in CTN in a daily dose 10 mg maximum is safe and can be used for inhibition of CTN progression.

References

  1. Ким И. Г. Отдаленные результаты трансплантации почки и факторы риска хронического отторжения: Дис. канд. мед. наук. М.; 1999.
  2. Столяревт Е. С, Ким И. Г., Ильинский И. М. и др. К вопросу о значении специфических антигензависимых и неспецифических факторов в патогенезе хронической трансплантационной нефропатии. Нефрол. и диализ. 2001; 3 (3): 335-344.
  3. Томилина Н. А., Ким И. Г. Факторы риска позднего прекращения функции почки. Нефрол. и диализ. 2000; 2 (4): 260-273.
  4. Шумаков В. И., Мойсюк Я. Г., Томилина Н. А. и др. Трансплантация почки. В кн.: Шумаков В. И. (ред.) Трансплантология: Руководство. М: Медицина; 1995. 194-196.
  5. Шумаков В. И., Мойсюк Я. Г., Томилина Н. А. и др. Трансплантация почки. В кн.: Тареева И. Е. (ред.) Нефрология: Руководство. М.: Медицина; 2000. 667-678.
  6. Fellstrom B. Progression of chronic renal transplant dysfunction. Transplant. Proc. 2001; 33: 3355-3356.
  7. Kahan B. D., Ponticelli C. Principles and practice of renal transplantation. 2000.
  8. Kasiske B. L. Clinical correlates to chronic renal allograft rejection. Kidney Int. 1997; 52 (suppl. 63): 71-74.
  9. Малое И. П. Гистологическое и иммуноморфологическое исследование аллотрансплантированных почек в позднем послеоперационном периоде: Дис. ... канд. мед. наук. М.; 1999.
  10. Столяревич Е. С. Хроническая трансплантационная неф- ропатия: клинико-морфологические сопоставления и факторы прогрессирования: Дис. ... канд. мед. наук. М. 2002.
  11. Colvin R. The renal allograft biopsy. Kidney Int. 1996; 50 1069-1082.
  12. Dische F. Renal pathology. New York: Oxford university press: 1995. 216.
  13. Soles K. Graft atherosclerosis and chronic rejection in the kidney. Transplant. Proc. 1997; 29: 2541.
  14. Soles K. Renal allograft histopathology. Nephrol. Dial. Transplant. 1995; 15: 44-50.
  15. Paul L. С Chronic allograft nephropathy: An update. Kidney Int. 1999; 56: 783-793.
  16. Paul L. С Immunologic risk factor for chronic renal allograft dysfunction. Transplantation 2001; 71 (11, suppl. 5): 17-24.
  17. Border W. A., Noble N. A. TGF-p in kidney fibrosis: A target for gene therapy. Kidney Int. 1997; 51: 1388-1396.
  18. Campistol J. M., Inigo P., Larios S. et al. Role transforming growth factor-pi in the progression of chronic allograft nephropathy. Nephrol. Dial. Transplant. 2001; 16 (suppl. 1): 114- 116.
  19. Campistol J. M., Inigo P., Jimenez W. et al. Losartan decreases plasma levels of TGF-beta 1 in transplant patients with chron ic allograft nephropathy. Kidney Int. 1999; 56: 714-719.
  20. Cuhaci В., Kumar M. S., Bloom R. D. et al. Transforming growth factor-p levels in human allograft chronic fibrosis correlate with rate of decline in renal function. Transplantation 1999; 68 (6): 785-790.
  21. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996; 49: 578-597.
  22. Inigo P., Campistol J. M., Lario S. Effects of losartan and amlodipine on intrarenal hemodynamic and TGF-pi plasma lev- els in a crossover trial in renal transplant recipients. J. Am. Soc. Nephrol. 2001; 12: 822-827.
  23. Klahr S., Morrissey J. J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal dis- ease. Kidney Int. 2000; 57 (suppl. 75): 7-14.
  24. Есаян А. М., Каюков И. Г., Титова В. А. Влияние ангиотензин-I конвертирующего фермента эналаприла на темпы прогрессирования хронической почечной недостаточности у больных с различной степенью нарушений функционального состояния почек. Тер. арх. 1995; 6: 57-59.
  25. Кутырина И. М., Тареева И. Е., Шешакова М. В. и др. Антипротеинурическое действие ингибиторов ангиотензин-превращающего фермента при хроническом гломерулонефрите и диабетической нефропатии. Тер. арх. 1994; 66 (6): 19-22.
  26. Anderson S., Rennke Н. С, Brenner В. М. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rats.J. Clin. Invest. 1986; 77: 1993-2000.
  27. Locatelli F., Del Vecchio L., Andrulli S. et al. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection. Kidney Int. 2002; 62 (suppl. 82): 53-60.
  28. Locatelli F., Carbarns I. R., Maschio G. et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int. 1997; 52 (suppl. 63): 63-66.
  29. Maschio G., Alberti D., Locatelli F. et al. Angiotensin-convert ing enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J. Cardiovasc. Pharmacol. 1999; 33 (suppl. 1): 16-20.
  30. Maschio G, Alberti D., Locatelli F. et al. Effect of the angi- otensin-converting enzyme inhibitors benazepril on the pro- gression of chronic renal insufficiency. N. Engl. J. Med. 1996; 334 (15): 939-945.
  31. Remuzzi G. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.
  32. Багдасарян А. Р., Столяревич Е. С, Суханов А. В. и др. Влияние эналаприла на скорость прогрессирования хронической трансплантационной нефропатии. Нефрол. и диализ. 2003; 5 (1): 33-42.

Statistics

Views

Abstract - 84

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2003 Tomilina N.A., Bagdasaryan A.R., Stolyarevich E.S., Sukhanov A.V., Fedorova N.D., Ilyinsky I.M., Tyrin V.V., Frolov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies